Acadia Pharmaceuticals Inc. (ACAD)

Price$21.25

Favorite Metrics

Price vs S&P 500 (26W)-1.87%

Price vs S&P 500 (4W)1.26%

Market Capitalization$3.73B

P/E Ratio (Annual)9.54x

All Metrics

P/CF (Annual)33.96x

Book Value / Share (Quarterly)$7.21

P/TBV (Annual)4.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.83%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)-21.17%

Gross Margin (TTM)91.71%

Net Profit Margin (TTM)44.97%

EPS (TTM)$2.28

10-Day Avg Trading Volume1.50M

EPS Excl Extra (TTM)$2.28

Revenue Growth (5Y)15.68%

EPS (Annual)$2.30

ROI (Annual)31.86%

Gross Margin (Annual)91.69%

Net Profit Margin (5Y Avg)-4.95%

Cash / Share (Quarterly)$4.81

P/E Basic Excl Extra (TTM)9.54x

Revenue Growth QoQ (YoY)9.39%

P/E Normalized (Annual)9.54x

ROA (Last FY)25.00%

Revenue Growth TTM (YoY)-13.64%

EBITD / Share (TTM)$0.64

ROE (5Y Avg)3.38%

Operating Margin (TTM)10.34%

Cash Flow / Share (Annual)$0.04

P/B Ratio3.04x

P/B Ratio (Quarterly)3.68x

Net Income / Employee (Annual)$0

EV / Revenue (TTM)3.52x

Net Interest Coverage (TTM)-30.69x

ROA (TTM)29.77%

EPS Growth QoQ (YoY)84.61%

EV / EBITDA (TTM)26.93x

EPS Incl Extra (Annual)$2.30

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)3.49x

3-Month Avg Trading Volume1.60M

52-Week Price Return46.43%

EV / Free Cash Flow (Annual)461.30x

P/E Incl Extra (TTM)9.54x

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$6.57

P/S Ratio (Annual)3.48x

Asset Turnover (Annual)0.69x

52-Week High$28.35

Operating Margin (5Y Avg)-10.93%

EPS Excl Extra (Annual)$2.30

Tangible BV CAGR (5Y)9.93%

26-Week Price Return2.11%

Quick Ratio (Annual)3.49x

13-Week Price Return-18.16%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.83x

Enterprise Value$2,909.884

Revenue / Share Growth (5Y)14.54%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)23.88%

Revenue / Employee (Annual)$1

Inventory Turnover (Annual)3.14x

Pretax Margin (Annual)12.96%

Cash / Share (Annual)$4.81

3-Month Return Std Dev41.47%

Gross Margin (5Y Avg)94.35%

Net Income / Employee (TTM)$0

ROE (Last FY)31.86%

Net Interest Coverage (Annual)-30.69x

EPS Basic Excl Extra (Annual)$2.30

P/FCF (TTM)12.65x

Receivables Turnover (TTM)7.51x

EV / Free Cash Flow (TTM)461.30x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.28

Receivables Turnover (Annual)9.73x

ROI (TTM)41.90%

P/S Ratio (TTM)4.51x

Pretax Margin (5Y Avg)-8.60%

Revenue / Share (Annual)$6.31

Tangible BV / Share (Annual)$6.57

Forward P/E48.36x

Price vs S&P 500 (52W)16.60%

P/E Ratio (TTM)9.54x

EPS Growth TTM (YoY)117.79%

Year-to-Date Return-18.53%

5-Day Price Return-3.59%

EPS Normalized (Annual)$2.30

ROA (5Y Avg)0.90%

Net Profit Margin (Annual)36.49%

Month-to-Date Return-2.25%

Cash Flow / Share (TTM)$-0.88

EBITD / Share (Annual)$0.64

Operating Margin (Annual)9.78%

LT Debt / Equity (Annual)0.01x

P/CF (TTM)33.96x

ROI (5Y Avg)3.38%

P/E Excl Extra (TTM)9.54x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$2.28

P/TBV (Quarterly)4.04x

P/B Ratio (Annual)3.68x

Inventory Turnover (TTM)3.14x

Pretax Margin (TTM)13.43%

Book Value / Share (Annual)$7.21

Price vs S&P 500 (13W)-18.85%

Beta0.89x

P/FCF (Annual)591.24x

Revenue / Share (TTM)$4.80

ROE (TTM)41.90%

52-Week Low$14.08

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.85

3.93

4.00

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ACADAcadia Pharmaceuticals Inc.	4.51x	-13.64%	91.71%	—	$21.25
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises in neurological and rare diseases. Its neurological franchise is anchored by NUPLAZID (pimavanserin), the first FDA-approved treatment for Parkinson's disease psychosis, while its rare disease franchise is built on DAYBUE, the first FDA-approved treatment for Rett syndrome. The company's clinical pipeline includes programs targeting Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and other neurological disorders.